Tirzepatide is a single engineered peptide that engages two incretin receptors at once — the GLP-1 receptor and the GIP receptor. This overview examines how that dual mechanism is described in the primary literature, why it was long considered implausible, and what controlled studies have actually reported.

Why a dual incretin agonist drew attention

Incretin-based pharmacology has been dominated for more than a decade by molecules that mimic a single gut hormone, glucagon-like peptide-1 (GLP-1). Tirzepatide (originally coded LY3298176) departs from that template: it was engineered to activate two incretin receptors simultaneously, the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor.¹ Because it combines two incretin activities in one chain, the compound has been nicknamed a "twincretin" in the review literature.⁶

The interest is not simply that two receptors are better than one. For years, GIP was widely written off as a therapeutic target in type 2 diabetes, because supraphysiological GIP infusions failed to produce a meaningful insulin response in people with the disease.⁶ The observation that co-activating GIP alongside GLP-1 appeared to restore or amplify metabolic responses is what makes tirzepatide a genuinely unusual case study in receptor pharmacology, and it is the reason the mechanism has been dissected so closely in cell, rodent, and human research.²

Incretin biology: GLP-1 and GIP

To follow the mechanism, it helps to revisit the two hormones tirzepatide imitates. Incretins are peptides released from enteroendocrine cells of the gut after nutrient intake, and they account for a substantial fraction of the insulin response to an oral, rather than intravenous, glucose load. The two dominant human incretins are GLP-1 and GIP.

GLP-1

GLP-1 is produced by intestinal L-cells and also within the central nervous system, and it acts through a class B G-protein-coupled receptor. A detailed review of GLP-1 physiology notes that the hormone regulates islet function, satiety, and gut motility, and that its receptor is expressed across pancreatic, neural, cardiovascular, and gastrointestinal tissues.³ In pancreatic beta cells, GLP-1 receptor activation raises intracellular cyclic AMP and potentiates insulin secretion in a glucose-dependent manner — meaning the effect scales with prevailing glucose and is minimal at normal glucose levels. The same review emphasises that many downstream effects attributed to GLP-1, including appetite suppression, are mediated through neural circuits rather than direct receptor expression in every target tissue.³

GIP

GIP is secreted by intestinal K-cells and is quantitatively the larger incretin in healthy physiology. Like GLP-1, it stimulates glucose-dependent insulin release through its own receptor. GIP also influences adipose tissue and lipid handling, and this dual footprint on both insulin secretion and fat metabolism is part of why co-agonism was hypothesised to add value beyond GLP-1 alone.¹ Historically, the apparent loss of GIP responsiveness in type 2 diabetes discouraged its pharmacological development; the tirzepatide programme reopened that question by pairing GIP activity with GLP-1 activity in a single molecule.⁶

The molecular mechanism of tirzepatide

Structurally, tirzepatide is a synthetic 39-amino-acid peptide built on the GIP sequence and modified with a C20 fatty-diacid moiety. That acylation promotes albumin binding, which slows clearance and supports a once-weekly administration interval in the studies that characterised it.¹ The discovery report described the peptide activating both GIP and GLP-1 receptor signalling in cell lines and driving glucose-dependent insulin secretion through both receptors in mice.¹

The most closely studied feature of the mechanism is that the two receptor activities are not symmetric. A detailed pharmacology study calculated receptor occupancy at clinically relevant concentrations and reported a greater degree of engagement at the GIP receptor than at the GLP-1 receptor — an "imbalanced" profile.² At the GIP receptor, tirzepatide behaved much like native GIP. At the GLP-1 receptor, however, it showed biased agonism: it favoured cyclic-AMP generation over recruitment of beta-arrestin, and it drove weaker receptor internalisation than native GLP-1.²

Why might that bias matter? In isolated islet experiments described in the same study, beta-arrestin-1 appeared to limit the insulin response to GLP-1, but not to GIP or to tirzepatide. The authors proposed that by under-recruiting beta-arrestin at the GLP-1 receptor, tirzepatide could sustain a stronger insulin-secretory signal than a conventional GLP-1 agonist.² This is a mechanistic hypothesis grounded in cell and rodent data, not a demonstrated clinical mechanism, and the distinction is important when interpreting the compound.

Downstream metabolic effects in experimental models

Across the mechanistic literature, dual receptor engagement is linked to several convergent metabolic readouts. These are best read as effects observed in cell systems, rodent models, and human trials rather than guaranteed outcomes.

Glucose-dependent insulin secretion. Both GIP and GLP-1 receptor signalling potentiate insulin release only when glucose is elevated, a property that constrains the hypoglycaemia risk seen with some other agents. In mice, tirzepatide improved glucose tolerance by acting through both receptors.¹

Glucagon dynamics. GLP-1 receptor activity is associated with suppression of glucagon secretion in the glucose-dependent range, which lowers hepatic glucose output. A mechanistic review of tirzepatide noted lower prandial insulin and glucagon concentrations relative to a selective GLP-1 agonist, alongside apparent improvements in insulin sensitivity.⁴

Appetite and body weight. With chronic dosing in mice, tirzepatide reduced body weight and food intake to a significantly greater degree than a GLP-1 receptor agonist comparator.¹ The relative contribution of the GIP arm to appetite in humans, however, remains contested — a point the reviews are careful to flag, since GIP reduces food intake in rodents but that specific effect has not been cleanly demonstrated in people.⁴

Lipid and adipose effects. Because GIP signalling touches adipocyte biology, part of the rationale for co-agonism was a broader influence on lipid metabolism and energy partitioning than GLP-1 monotherapy achieves.¹ Preclinical and early clinical data have been used to argue for greater metabolic flexibility, though the human mechanistic picture is still being assembled.⁴

What controlled human trials report

The clinical characterisation of tirzepatide progressed through a phase 2 dose-ranging trial and the phase 3 SURPASS (type 2 diabetes) and SURMOUNT (obesity) programmes. The phase 2 study compared four tirzepatide doses against placebo and the selective GLP-1 agonist dulaglutide over 26 weeks, and reported dose-dependent reductions in HbA1c that did not plateau, together with larger weight change than dulaglutide.⁵

In the head-to-head SURPASS-2 trial, tirzepatide at 5, 10, and 15 mg was compared directly with semaglutide 1 mg over 40 weeks in adults with type 2 diabetes; all three tirzepatide doses were reported as non-inferior and statistically superior to semaglutide for the change in HbA1c, with greater body-weight reductions.⁷ A separate trial (SURPASS-3) compared tirzepatide with titrated insulin degludec and reported larger HbA1c and body-weight reductions with the peptide.⁸ In the obesity setting, SURMOUNT-1 studied participants without diabetes and reported mean weight changes of roughly −15% to −21% across doses over 72 weeks versus about −3% with placebo.⁹

The table below summarises headline readouts from these primary trials. Values are drawn directly from the cited reports and describe study populations, not individuals.

Across these programmes, the most commonly reported adverse events were gastrointestinal — nausea, diarrhoea, and vomiting — generally described as mild to moderate and more frequent during dose escalation and at higher doses.⁴ Cardiovascular events were adjudicated across the trial programme; a meta-analytic summary did not identify a hazard ratio above 1.0 for major adverse cardiovascular events versus pooled comparators, though the event numbers were low and dedicated cardiovascular-outcome data continue to mature.⁴ A focused review of the cardiovascular literature framed any cardiovascular signals as based on preclinical and secondary clinical data rather than a completed outcomes trial.¹⁰

Mono-, dual, and triple agonism compared

Placing tirzepatide on a spectrum clarifies what "dual agonism" adds. A selective GLP-1 receptor agonist such as semaglutide engages one incretin receptor; the research question tirzepatide poses is whether adding GIP activity to the same molecule changes the metabolic output. The comparative trials above were designed partly to answer that, and the phase 2 and SURPASS-2 data were the studies that placed the dual agonist ahead of a single-receptor comparator on the measured endpoints.⁵⁷

The logic has since been extended further. Investigational triple agonists such as retatrutide add glucagon-receptor activity to the GIP/GLP-1 pairing, testing whether a third pathway contributes additional metabolic effects. Tirzepatide sits at the two-receptor midpoint of this design progression, and its imbalanced, biased mechanism is what distinguishes it from both simpler and more complex incretin analogues.² For research settings, this makes it a useful reference compound when comparing receptor-selectivity hypotheses across incretin classes.

Open questions and evidence limits

Despite the depth of characterisation, several mechanistic uncertainties are openly acknowledged in the reviews. The first is the human role of the GIP arm. While GIP reduces food intake and body weight in rodents, that specific action has not been demonstrated in humans, and it remains unresolved whether GIP-receptor agonism restores insulin secretion in people with type 2 diabetes who were previously unresponsive to GIP.⁴ A second question is whether the observed clinical advantage reflects the GIP contribution, the biased GLP-1 signalling, the imbalanced occupancy, or some combination — a decomposition the current data cannot fully make.²

There is also the general caution that GLP-1-receptor localisation is technically difficult to measure, so attributing effects to direct versus indirect (neural) receptor action is not straightforward.³ These are not peripheral caveats; they are central to interpreting why the molecule performs as it does in the reported studies.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.